Mirtazapine versus fluoxetine in the treatment of panic disorder.
about
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersManagement of treatment-resistant panic disorderReview of the use of mirtazapine in the treatment of depression.Psychopharmacology of anxiety disorders.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Weight gain, obesity, and psychotropic prescribing.Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.Antidepressant use and body mass index change in overweight adolescents: a historical cohort study.Psychiatric medication-induced obesity: a review.Mirtazapine: a review of its clinical efficacy and tolerability.INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALSReduced 5-HT(2A) receptor signaling following selective bilateral amygdala damage.A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies.New treatment options for panic disorder: clinical trials from 2000 to 2010.Obesity and psychotropics.Antidepressants and benzodiazepines for panic disorder in adults.Panic Attacks During Escalation of Mirtazapine.Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.
P2860
Q27009995-69BC0F96-144B-478D-8965-E98D602E3E5BQ33814038-DF984407-3D9F-4861-9594-487D89B6F5F2Q34190102-3B8906F0-416A-436E-B95A-0CC0A8B07EE0Q34228150-E37F4130-6C9C-4288-97DA-37AB767D3B3DQ34465555-0828344A-BCCF-430A-9CE6-E1E51AF30907Q34557537-46385C4C-8DA6-4931-866C-558F57C00680Q34560858-F2F5DB9E-9D27-42DC-B257-49AC7E221820Q34992286-47620DB9-2AC5-4D2B-A4E0-1B9E30552350Q35746806-01293A3D-2DF6-4281-80AD-5002C57116DBQ36150725-7C913F0F-53D0-4472-91A5-D29A3EC1EFDAQ37041164-597E8BC5-7BA9-411D-A479-EBD886DC6830Q37131261-6A29FDF1-C8C7-4473-8063-C7EE42B3BFF2Q37533880-440EE03E-D098-46EF-8728-81557977BFCFQ37763406-26A31989-61A9-45ED-9F58-6AABCA11C870Q37845855-38B0FB16-02A3-4FB3-A7E8-E5760042A8CAQ37954390-F5F865B5-F1FD-4F62-9997-6C4F2D78BEC0Q38952014-ECE19B37-9C10-496F-A4DC-9C012DCEA0ECQ40621839-29E5BDD2-2F6E-4277-BB5B-C6F1CE6FFCD8Q44026742-1409D070-3E51-41A6-A292-D1342CB266D2Q53091817-E036B2D9-499A-4129-997B-180C4E2398D6
P2860
Mirtazapine versus fluoxetine in the treatment of panic disorder.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@ast
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@en
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@nl
type
label
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@ast
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@en
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@nl
prefLabel
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@ast
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@en
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@nl
P2093
P2860
P1476
Mirtazapine versus fluoxetine in the treatment of panic disorder.
@en
P2093
E A Busnello
J V Busnello
M Kauer-Sant'Anna
P2860
P304
P356
10.1590/S0100-879X2001001000010
P407
P577
2001-10-01T00:00:00Z